Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–97. https://doi.org/10.1001/JAMA.2016.13985.

Article  CAS  Google Scholar 

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290(1):140–205. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2019.08.014.

Article  Google Scholar 

Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet (London, England). 2017;390(10106):1962–71. https://doi.org/10.1016/S0140-6736(17)32290-0.

Article  CAS  Google Scholar 

Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018;38(3):592–8. https://doi.org/10.1161/ATVBAHA.117.310217.

Article  CAS  Google Scholar 

Bansal S, Ruzza A, Sawhney JPS, et al. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021;15(6):814–21. https://doi.org/10.1016/J.JACL.2021.10.003.

Article  Google Scholar 

Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–95. https://doi.org/10.1001/JAMACARDIO.2019.3780.

Article  Google Scholar 

Pinzon Grimaldos A, Bini S, Pacella I, et al. The role of lipid metabolism in shaping the expansion and the function of regulatory T cells. Clin Exp Immunol. 2022;208(2):181–92. https://doi.org/10.1093/cei/uxab033.

Article  Google Scholar 

Feingold KR. Introduction to Lipids and Lipoproteins. MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK305896/. Accessed August 29, 2021.

Björnson E, Adiels M, Taskinen MR, Borén J. Kinetics of plasma triglycerides in abdominal obesity. Curr Opin Lipidol. 2017;28(1):11–8. https://doi.org/10.1097/MOL.0000000000000375.

Article  CAS  Google Scholar 

Borén J, Taskinen MR, Björnson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022. https://doi.org/10.1038/S41569-022-00676-Y.

Article  Google Scholar 

Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med. 2012;2012. https://doi.org/10.1155/2012/947417.

Lopez-Miranda J, Williams C, Larion D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr. 2007;98(3):458–73. https://doi.org/10.1017/S000711450774268X.

Article  CAS  Google Scholar 

Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020;26(6):964–73. https://doi.org/10.1038/S41591-020-0934-0.

Article  CAS  Google Scholar 

Zhang R, Zhang K. An updated ANGPTL3–4–8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues. Prog Lipid Res. 2021;85. https://doi.org/10.1016/J.PLIPRES.2021.101140.

Bini S, D’Erasmo L, Di Costanzo A, Minicocci I, Pecce V, Arca M. The interplay between angiopoietin-like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases? Int J Mol Sci. 2021;22(2):1–16. https://doi.org/10.3390/ijms22020742.

Article  CAS  Google Scholar 

Tikkanen E, Minicocci I, Hällfors J, et al. Metabolomic signature of angiopoietin-like protein 3 deficiency in fasting and postprandial state. Arterioscler Thromb Vasc Biol. 2019;39(4):665–74. https://doi.org/10.1161/ATVBAHA.118.312021.

Article  CAS  Google Scholar 

Banfi S, Gusarova V, Gromada J, et al. Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice. https://doi.org/10.1073/pnas.1717420115.

Minicocci I, Montali A, Robciuc MR, et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2012;97(7):E1266–75. https://doi.org/10.1210/jc.2012-1298.

Article  CAS  Google Scholar 

Conklin D, Gilbertson D, Taft DW, et al. Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics. 1999;62(3):477–82. https://doi.org/10.1006/GENO.1999.6041.

Article  CAS  Google Scholar 

Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751–6. https://doi.org/10.1073/PNAS.1217552109.

Article  CAS  Google Scholar 

Inaba T, Matsuda M, Shimamura M, et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem. 2003;278(24):21344–51. https://doi.org/10.1074/jbc.M213202200.

Article  CAS  Google Scholar 

Li H, Liu J. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem J. 2012;443(3):757–68. https://doi.org/10.1042/BJ20111645.

Article  CAS  Google Scholar 

Minicocci I, Tikka A, Poggiogalle E, et al. Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. J Lipid Res. 2016;57(6):1097–107. https://doi.org/10.1194/jlr.P066183.

Article  CAS  Google Scholar 

Li Y, Sun L, Xu H, et al. Angiopoietin-like protein 3 modulates barrier properties of human glomerular endothelial cells through a possible signaling pathway involving phosphatidylinositol-3 kinase/protein kinase B and integrin alphaVbeta3. Acta Biochim Biophys Sin (Shanghai). 2008;40(6):459–65. https://doi.org/10.1111/J.1745-7270.2008.00421.X.

Article  CAS  Google Scholar 

Shimamura M, Matsuda M, Kobayashi S, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun. 2003;301(2):604–9. https://doi.org/10.1016/S0006-291X(02)03058-9.

Article  CAS  Google Scholar 

Ono M, Shimizugawa T, Shimamura M, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem. 2003;278(43):41804–9. https://doi.org/10.1074/jbc.M302861200.

Article  CAS  Google Scholar 

Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61(317):jlr.RA120000781. https://doi.org/10.1194/jlr.ra120000781.

Camenisch G, Pisabarro MT, Sherman D, et al. ANGPTL3 Stimulates endothelial cell adhesion and migration via integrin αvβ3 and induces blood vessel formation in vivo. J Biol Chem. 2002;277(19):17281–90. https://doi.org/10.1074/JBC.M109768200.

Article  CAS  Google Scholar 

Bini S, Pecce V, Di Costanzo A, et al. The fibrinogen-like domain of ANGPTL3 facilitates lipolysis in 3T3-L1 cells by activating the intracellular erk pathway. Biomolecules. 2022;12(4):585. https://doi.org/10.3390/biom12040585.

Article  CAS  Google Scholar 

Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim. 2006;55(1):27–34. https://doi.org/10.1538/EXPANIM.55.27.

Article  CAS  Google Scholar 

Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296–307. https://doi.org/10.1194/JLR.M054882.

Article  CAS  Google Scholar 

Wang Y, McNutt MC, Banfi S, et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A. 2015;112(37):11630–5. https://doi.org/10.1073/pnas.1515374112.

Article  CAS  Google Scholar 

Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40(2):189–97. https://doi.org/10.1038/NG.75.

Article  CAS  Google Scholar 

Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220–7. https://doi.org/10.1056/NEJMoa1002926.

Article  CAS  Google Scholar 

Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54(12):3481–90. https://doi.org/10.1194/jlr.P039875.

Article  CAS  Google Scholar 

Fazio S, Sidoli A, Vivenzio A, et al. A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene. J Intern Med. 1991;229(1):41–7. https://doi.org/10.1111/J.1365-2796.1991.TB00304.X.

Article  CAS  Google Scholar 

Arca M, D’Erasmo L, Minicocci I. Familial combined hypolipidemia : ANGPTL3 deficiency. Curr Opin Lipidol. 2020;31(2):41–8. https://doi.org/10.1097/MOL.0000000000000668.

Article  CAS  Google Scholar 

Di Costanzo A, Di Leo E, Noto D, et al. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: a comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. J Clin Lipidol. 2017;11(5):1234–42. https://doi.org/10.1016/j.jacl.2017.06.013.

Article  Google Scholar 

D’Erasmo L, Neufeld T, Di Martino M, et al. The impact of ANGPTL3 deficiency on hepatic steatosis: Observations from carriers of loss-of-function mutations. Atherosclerosis. 2020;315: e17. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2020.10.064.

Article  Google Scholar 

Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054–63. https://doi.org/10.1016/j.jacc.2017.02.030.

Article  CAS  Google Scholar 

Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–21. https://doi.org/10.1056/nejmoa1612790.

Article  CAS  Google Scholar 

Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308–17. https://doi.org/10.1194/JLR.M054890.

Article  CAS  Google Scholar 

•• Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–86. https://doi.org/10.1161/CIRCULATIONAHA.118.039107. This paper shows the results of 2 Phase 1 studies proving the efficacy and safety of in hypertriglyceridemic subjects showing comparable results that that observed in carrying loss of function mutations in ANGPTL3.

Article  CAS  Google Scholar 

•• Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–20. https://doi.org/10.1056/nejmoa2004215. This Phase III trials showed that homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy plus Evinacumab had a 49% reduction from baseline in LDL-C at 24 weeks as compared the small increase in the placebo group.

Article  CAS  Google Scholar 

• Reeskamp LF, Millar JS, Wu L, et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report. Arterioscler Thromb Vasc Biol. 2021;41(5):1753–9. https://doi.org/10.1161/ATVBAHA.120.315204. In this small kinetic study, ANGPTL3 inhibition with